Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Opportunity for exploring anti-PD-L1 and anti-PD-1 agents in combination with targeted therapies
A group of Italian and Swiss researchers have found a correlation between PD-L1 expression and EGFR mutation, as well as between PD-1 expression and KRAS mutations in a cohort of molecularly selected patients with non-small-cell lung cancer (NSCLC).
To read the rest of this story visit the ESMO site.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.